Cargando…
The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example
BACKGROUND: Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are. METHODS: To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dich...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Association for Cancer Research
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627261/ https://www.ncbi.nlm.nih.gov/pubmed/35984990 http://dx.doi.org/10.1158/1055-9965.EPI-22-0495 |
_version_ | 1784822924533825536 |
---|---|
author | Duchesneau, Emilie D. Jackson, Bradford E. Webster-Clark, Michael Lund, Jennifer L. Reeder-Hayes, Katherine E. Nápoles, Anna M. Strassle, Paula D. |
author_facet | Duchesneau, Emilie D. Jackson, Bradford E. Webster-Clark, Michael Lund, Jennifer L. Reeder-Hayes, Katherine E. Nápoles, Anna M. Strassle, Paula D. |
author_sort | Duchesneau, Emilie D. |
collection | PubMed |
description | BACKGROUND: Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are. METHODS: To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dichotomous exposure, dichotomous exposure excluding immortal time, time-varying exposure, landmark analysis, clone-censor-weight method), using surgical resection among women with metastatic breast cancer as an example. All adult women diagnosed with incident metastatic breast cancer from 2013–2016 in the National Cancer Database were included. To quantify immortal time bias, we also conducted a simulation study where the “true” relationship between surgical resection and mortality was known. RESULTS: 24,329 women (median age 61, IQR 51–71) were included, and 24% underwent surgical resection. The largest association between resection and mortality was observed when using a dichotomized exposure [HR, 0.54; 95% confidence interval (CI), 0.51–0.57], followed by dichotomous with exclusion of immortal time (HR, 0.62; 95% CI, 0.59–0.65). Results from the time-varying exposure, landmark, and clone-censor-weight method analyses were closer to the null (HR, 0.67–0.84). Results from the plasmode simulation found that the time-varying exposure, landmark, and clone-censor-weight method models all produced unbiased HRs (bias −0.003 to 0.016). Both standard dichotomous exposure (HR, 0.84; bias, −0.177) and dichotomous with exclusion of immortal time (HR, 0.93; bias, −0.074) produced meaningfully biased estimates. CONCLUSIONS: Researchers should use time-varying exposures with a treatment assessment window or the clone-censor-weight method when immortal time is present. IMPACT: Using methods that appropriately account for immortal time will improve evidence and decision-making from research using real-world data. |
format | Online Article Text |
id | pubmed-9627261 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | American Association for Cancer Research |
record_format | MEDLINE/PubMed |
spelling | pubmed-96272612023-01-05 The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example Duchesneau, Emilie D. Jackson, Bradford E. Webster-Clark, Michael Lund, Jennifer L. Reeder-Hayes, Katherine E. Nápoles, Anna M. Strassle, Paula D. Cancer Epidemiol Biomarkers Prev Research Articles BACKGROUND: Studies evaluating the effects of cancer treatments are prone to immortal time bias that, if unaddressed, can lead to treatments appearing more beneficial than they are. METHODS: To demonstrate the impact of immortal time bias, we compared results across several analytic approaches (dichotomous exposure, dichotomous exposure excluding immortal time, time-varying exposure, landmark analysis, clone-censor-weight method), using surgical resection among women with metastatic breast cancer as an example. All adult women diagnosed with incident metastatic breast cancer from 2013–2016 in the National Cancer Database were included. To quantify immortal time bias, we also conducted a simulation study where the “true” relationship between surgical resection and mortality was known. RESULTS: 24,329 women (median age 61, IQR 51–71) were included, and 24% underwent surgical resection. The largest association between resection and mortality was observed when using a dichotomized exposure [HR, 0.54; 95% confidence interval (CI), 0.51–0.57], followed by dichotomous with exclusion of immortal time (HR, 0.62; 95% CI, 0.59–0.65). Results from the time-varying exposure, landmark, and clone-censor-weight method analyses were closer to the null (HR, 0.67–0.84). Results from the plasmode simulation found that the time-varying exposure, landmark, and clone-censor-weight method models all produced unbiased HRs (bias −0.003 to 0.016). Both standard dichotomous exposure (HR, 0.84; bias, −0.177) and dichotomous with exclusion of immortal time (HR, 0.93; bias, −0.074) produced meaningfully biased estimates. CONCLUSIONS: Researchers should use time-varying exposures with a treatment assessment window or the clone-censor-weight method when immortal time is present. IMPACT: Using methods that appropriately account for immortal time will improve evidence and decision-making from research using real-world data. American Association for Cancer Research 2022-11-02 2022-08-19 /pmc/articles/PMC9627261/ /pubmed/35984990 http://dx.doi.org/10.1158/1055-9965.EPI-22-0495 Text en ©2022 The Authors; Published by the American Association for Cancer Research https://creativecommons.org/licenses/by-nc-nd/4.0/This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. |
spellingShingle | Research Articles Duchesneau, Emilie D. Jackson, Bradford E. Webster-Clark, Michael Lund, Jennifer L. Reeder-Hayes, Katherine E. Nápoles, Anna M. Strassle, Paula D. The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example |
title | The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example |
title_full | The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example |
title_fullStr | The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example |
title_full_unstemmed | The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example |
title_short | The Timing, the Treatment, the Question: Comparison of Epidemiologic Approaches to Minimize Immortal Time Bias in Real-World Data Using a Surgical Oncology Example |
title_sort | timing, the treatment, the question: comparison of epidemiologic approaches to minimize immortal time bias in real-world data using a surgical oncology example |
topic | Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9627261/ https://www.ncbi.nlm.nih.gov/pubmed/35984990 http://dx.doi.org/10.1158/1055-9965.EPI-22-0495 |
work_keys_str_mv | AT duchesneauemilied thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT jacksonbradforde thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT websterclarkmichael thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT lundjenniferl thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT reederhayeskatherinee thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT napolesannam thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT strasslepaulad thetimingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT duchesneauemilied timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT jacksonbradforde timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT websterclarkmichael timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT lundjenniferl timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT reederhayeskatherinee timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT napolesannam timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample AT strasslepaulad timingthetreatmentthequestioncomparisonofepidemiologicapproachestominimizeimmortaltimebiasinrealworlddatausingasurgicaloncologyexample |